

PHARMACIST-IN-CHARGE  
TRAINING PROGRAM

MODULE III

VERSION 4/2024

1

---

---

---

---

---

---

---

---

DISCLAIMER

- This training is intended to provide interested persons with an overview of Oregon Board of Pharmacy statutes and rules found in the Oregon Revised Statutes (ORS), chapters 475 and 689 and Oregon Administrative Rules (OAR), chapter 855 as they relate to the responsibilities of a Pharmacist-in-Charge (PIC)
- While the intent is to periodically update the material to comply with applicable laws and rules it is incumbent upon you to use the current and effective laws and rules.
- Where in conflict, the applicable law or rule takes precedence over information contained in this training.

2

---

---

---

---


---

---


---

---


TRAINING PROGRAM OVERVIEW



**Part I**  
Board  
PIC Qualifications, Limitations and Responsibilities  
Pharmacy Policies & Procedures  
Recordkeeping & Documentation



**Part II**  
Inspections  
Investigations



**Part III**  
Current Topics  
Resources

3

---

---

---

---

---

---

---

---

**CURRENT TOPICS**  
MODULE III



4

---

---

---

---

---

---

---

---

**ORS 413.550 & ORS 413.559**  
**ACCESSIBILITY: INTERPRETATION**

- Counseling [OAR 855-115-0145](#)

(5) When communicating (e.g., counseling, patient care services, billing) with a patient who prefers to communicate in a language other than English or who communicates in signed language, the pharmacist must work with a health care interpreter from the health care interpreter registry administered by the Oregon Health Authority under ORS 413.558 unless the pharmacist is proficient in the patient's preferred language.
- Dispensing: Interpretation [OAR 855-041-1133](#)
  - For a patient who prefers to communicate in a language other than English or who communicates in signed language, Pharmacist/Intern must work with OHA registered interpreter unless the Pharmacist is proficient in the patient's preferred language
  - Exceptions: Good faith effort or patient declined
  - Must provide PPE to interpreter if in-person
  - Must maintain records for each patient encounter
    - OHA registry interpreter- interpreter full name, registry number, and language interpreted
    - Good faith effort
- Patient Medical Record [OAR 855-041-1165](#)
  - Patient's preferred language for communication and prescription labeling

5

---

---

---

---

---

---

---

---

**ORS 689.564**  
**ACCESSIBILITY: DUAL LANGUAGE LABELS**

- [OAR 855-041-1132](#)

(1) Upon request of a prescriber, patient or a patient's agent, each drug dispensed by a pharmacy for a patient's self-administration must bear a label in both English and the language requested for an individual with limited English proficiency, defined as a person who is not fluent in the English language. This does not apply to a drug outlet dispensing a drug intended for administration by a healthcare worker.

(2) When dispensing a drug under (1), a pharmacy must provide labels and informational inserts in both English and one of the following languages: (a) Spanish; (b) Russian; (c) Somali; (d) Arabic; (e) Chinese (simplified); (f) Vietnamese; (g) Farsi; (h) Korean; (i) Romanian; (j) Swahili; (k) Burmese; (l) Nepali; (m) Amharic; and (n) Pashtu.

(3) The board must reassess and update (2) as necessary and at least every ten years.
- [OAR 855-041-1035](#)

(1) Each retail drug outlet and institutional drug outlet must have the following:

(g) Signage in a location easily seen by the public where prescriptions are dispensed or administered:

(B) Providing notification in each of the languages required in [OAR 855-041-1132](#) of the right to free, competent oral interpretation and translation services, including translated prescription labels, for patients who are of limited English proficiency, in compliance with federal and state regulations if the pharmacy dispenses prescriptions for a patient's self-administration;

6

---

---

---

---

---

---

---

---



7

---

---

---

---

---


---

---

---

---

---



8

---

---

---

---

---


---

---

---

---

---



9

---

---

---

---

---

---

---

---

---

---

**PRESCRIPTION READER ACCESSIBILITY**

- [OAR 855-041-1131](#)  
 A pharmacy shall notify each person to whom a prescription drug is dispensed that a prescription reader is available to the person upon request; a prescription reader is a device designed to audibly convey labeling information.  
 A pharmacy that provides a prescription reader shall make it available to the person for at least the duration of the prescription, shall confirm it is appropriate to address the person's visual impairment, and shall ensure that prescription labels are compatible with the prescription reader.  
 This requirement does not apply to an institutional drug outlet, dispensing a drug intended for administration by a healthcare provider.

10

---

---

---

---

---

---

---

---

**OPTIONS FOR PRESCRIPTION READERS**

11

---

---

---

---

---

---

---

---

**CONTINUING PHARMACY EDUCATION (CPE): CULTURAL COMPETENCY**

- [ORS 676.850](#)  
 Complete 2 hours of continuing pharmacy education related to cultural competency during each biennial license renewal cycle.
  - Approved by the Oregon Health Authority under ORS 413.450 -or-
    - [OHA Cultural Competence Continuing Education \(CCCE\)](#)
  - Any cultural competency CPE
    - [Pharmacy Learning Assistance Network \(ACPE\)](#) - Utilize this nationwide database to locate ACPE approved CPE on a specific topic (Law, Cultural Competency, Patient Safety)
- Enforcement of this requirement begins with the CPE period beginning
  - 7/1/2021 – 6/30/2023 for Pharmacists
  - 12/1/2021 – 11/30/2023 for Interns
  - 7/1/2023 – 6/30/2024 for COPTs and PTs

12

---

---

---

---

---

---

---

---

**CONTINUING PHARMACY EDUCATION (CPE): PAIN**

- [ORS 689.285](#)
- Complete one hour of continuing pharmacy education in pain management, provided by the Pain Management Commission of the Oregon Health Authority
  - Prior to initial licensure
  - With each license renewal
- [OHA Pain Management Commission CE Module](#)
- Enforcement of this requirement begins with the CPE period beginning
  - 7/1/2023-6/30/2025 for pharmacists

13

---

---

---

---

---

---

---

---

**OAR 855-135: CONTINUING PHARMACY EDUCATION (CPE) EFFECTIVE 7/1/2023**

<p><b>What's IN</b></p> <ul style="list-style-type: none"> <li>▪ Education that includes defined:           <ul style="list-style-type: none"> <li>▪ Learning objectives</li> <li>▪ Qualified instructors</li> <li>▪ Learning assessment</li> <li>▪ Program evaluation</li> </ul> </li> <li>▪ ACPE or board-approved programs</li> <li>▪ ACCME AMA Category I programs</li> <li>▪ Policy discussion at OBOP meeting</li> <li>▪ For board-approved programs           <ul style="list-style-type: none"> <li>▪ Applications submitted 45 days in advance</li> </ul> </li> </ul>	<p><b>What's OUT</b></p> <ul style="list-style-type: none"> <li>▪ Welcoming remarks;</li> <li>▪ Meals or social functions;</li> <li>▪ Business sessions</li> <li>▪ Unstructured discussion, Q/A</li> <li>▪ Degree programs;</li> <li>▪ Non-ACPE approved certificate programs;</li> <li>▪ Licensing or certification examinations;</li> </ul>	<ul style="list-style-type: none"> <li>▪ Skills training programs;</li> <li>▪ Software training programs;</li> <li>▪ Learning assessments;</li> <li>▪ Program evaluations; and</li> <li>▪ Attending CPE programs for which credit was not granted by the provider.</li> <li>▪ For board approved-programs           <ul style="list-style-type: none"> <li>▪ Post program approvals</li> </ul> </li> </ul>
--	---	--

14

---

---

---

---

---

---

---

---

**OAR 855-135: CONTINUING PHARMACY EDUCATION EFFECTIVE 7/1/2023**

- Applications for Program Approval
  - New board-approval application
- Instructors' Credit Toward CPE Hours
  - 2 hours per 1 hour spent delivering the program x1
  - Max 10 hours per renewal cycle
- Requirements for License Renewal (RPH, Intern, COPT & PT)
  - Must register with the CPE Monitor for tracking completed ACPE credit hours.
  - For each ACPE-approved program, the licensee must ensure that licensee program completion CPE credit was recorded in the CPE Monitor.
  - For each board-approved or ACCME accredited program, the licensee must ensure that licensee program completion CPE credit was recorded in the CPE Monitor or uploaded to the licensee's electronic licensing record with the board prior to submission of the license renewal.
  - Retain documentation of completed CPE for 6 years and must provide this documentation if requested by the board.

15

---

---

---

---

---

---

---

---

## SUBMITTING CPE ONLINE

**CPE Monitor**

- Free
  - All ACPE-accredited CPE
- Fee
  - Board-approved CPE
  - OHA Pain CPE
  - OBOP PIC Training
- ACCME

**e-Gov**

- Free
  - Board-approved CPE
    - OHA Pain CPE
    - OBOP PIC Training
  - ACCME

Welcome to Oregon Board of Pharmacy's Online License Services

If you wish to apply for a license or registration, create an existing license or registration, or request a certified copy of your license or registration, click one of the Register buttons below.

Returning Users

User ID:  Sign in your user ID

Password:  Sign in your password

Login

New User?

Register a New Personal Account  
Register a New Facility Account

---

---

---

---

---

---

---

---

---

---

---

---

16

## DRUG SUPPLY CHAIN SECURITY ACT (DSCSA) PHARMACY REQUIREMENTS EFFECTIVE 11/27/2023, ENFORCED 11/27/2024

- Verify licensure of all business partners (manufacturers, distributors, etc.)
- Receive, store, and provide product tracing documentation
- Accept prescription drugs with complete transaction information, history, and statement
- Retain received tracing documentation for six years (paper or electronic)
- Provide product tracing documentation when selling to a trading partner
- Develop procedures to investigate and handle suspect/illegitimate drugs
- Quarantine and investigate suspect drugs; if illegitimate, take action
- Notify FDA and trading partners about illegitimate drugs



Photo by John-Mark Smith: <https://www.pexels.com/photo/map-of-the-world-board-laid-open-on-brown-wooden-surface-32207/>

---

---

---

---

---

---

---

---

---

---

---

---

17

## DRUG TAKE BACK



- ORS 459A.200 to 459A.266
- OAR 855-041-1045 Returned Drugs and Devices
- OAR 855-041-1046 Secure and Responsible Drug Disposal
- The covered manufacturers will be required to pay all program costs including the costs of the collection kiosks and disposal services
- Compliance Officers will inspect the drop-off sites
- DEQ administers the program

---

---

---

---

---

---

---

---

---

---

---

---

18

**OAR 855-041-1092**  
**RETAIL DRUG OUTLET PHARMACY CLOSURES:  
 TEMPORARY, PERMANENT OR EMERGENCY**

- (1) Temporary
  - Post notification of closure- entrances, telephone greeting, internet
  - Provide patients with alternative options to receive prescription
  - Board notification
- (2) Permanent
  - Provide patients with notification of closure 15 calendar days prior to closure
  - Disposition of Rx and non-Rx drugs, devices and related supplies
  - Disposition of records
  - Lists for items to be completed prior to, on the date of/within 24 hours and within 30 days
- (3) Emergency
  - Follow temporary closure rules as soon as allowed by circumstances

19

---

---

---

---

---

---


---

---

---

---

**PHARMACY DESERTS**



- 90% US residents live within 5 miles of a community pharmacy
- 85% US residents receive medications from a community pharmacy
- Pharmacy desert = Patient >10 miles (or > 15 minutes) from a community pharmacy
- Board of Pharmacy rules permit:
  - Telepharmacies [OAR 855-139](#)
  - Pharmacy Prescription Kiosks [OAR 855-141](#)
  - Pharmacy Prescription Lockers [OAR 855-143](#)

Footnote: (1) U.S. State Pharmacy Desert Map. Retrieved from <https://www.ahrq.gov/research/publications/medication-access/medication-access-2018/>.  
 (2) U.S. HealthCare Service, 85 Percent of Country Lacks Adequate Prescription Access. Retrieved from <https://www.healthcare.gov/press/2018/s0818-pharm-desert/>

20

---

---

---

---

---

---

---

---

---

---

**SHORT-ACTING OPIOID ANTAGONISTS**

- 2023 HB 2395
  - "Naloxone" -> "Short-acting opioid antagonists"
- 2023 SB 450 -> [ORS 689.813](#)
  - Exempts from labeling requirements drug intended to reverse opioid overdose when drug is in the form of a nasal spray and is **prescribed and personally dispensed** by a health care provider.
- Ways to prescribe/dispense:
  - Under authority granted by [ORS 689.802](#) -> [OAR 855-115-0350](#)
  - Under statewide standing order issued pursuant to [ORS 689.808](#) by a State Health Officer with OHA
  - Under statewide protocol authority in [ORS 689.645](#) - IN PROGRESS



Photos accessed at <https://narcan.com/> and <https://opvee.com/how-to-get-opvee/>

21

---

---

---

---

---

---

---

---

---

---

## VACCINE ADMINISTRATION

- [2023 HB 2278](#) -> [ORS 689.645](#) -> [OAR 855-115-0305](#)
  - Permits Pharmacists to administer vaccines to persons who are six months of age or older if the vaccine administered is an influenza vaccine
- [2023 HB 2486](#) -> [ORS 689.645](#) -> [OAR 855-125-0305](#)
  - Permits COPT/PTs to perform the physical act of administering vaccines under the supervision of an appropriately trained and qualified Pharmacist



Photo by: Natalliya Vokhachik / https://www.pexels.com/photo/vaccine-for-covid-19-5832407/

22

---

---

---

---

---


---

---


---

---

---



✓ Compounding per the label



✗ Exempted from compounding  
[2024 HB 4010](#)

## COMPOUNDING

### OAR 855-045

- All drug compounding must adhere to standards of the United States Pharmacopeia (USP) and the National Formulary (NF) including:
  - USP <795> Pharmaceutical Compounding—Non-Sterile Preparations (05/01/2020 v. 2014); [USP <795> Pharmaceutical Compounding—Non-Sterile Preparations \(11/1/2023\)](#).
  - USP <797> Pharmaceutical Compounding—Sterile Preparations (05/01/2020 v. 2008); [USP <797> Pharmaceutical Compounding—Sterile Preparations \(11/1/2023\)](#).
  - USP <800> Hazardous Drugs—Handling in Healthcare Settings (07/01/2020 v. 2020);
  - USP <825> Radiopharmaceuticals—Preparation, Compounding, Dispensing, and Repackaging (12/01/2020 v. 2020);

23

---

---

---

---

---

---

---

---

---

---

## PUBLIC HEALTH PHARMACY FORMULARY ADVISORY COMMITTEE (PHPFAC)

- [ORS 689.649](#)
  - Committee comprised of 2 physicians, 2 nurse practitioners and 3 pharmacists appointed by the Governor
  - Committee recommends formulary items and protocols to the board for adoption via rulemaking
- [ORS 689.645](#) -> [OAR 855-115-0330](#) to [OAR 855-115-0345](#)
  - Allows a pharmacist to prescribe and dispense a drug or device included on the established formulary pursuant to a diagnosis by a healthcare practitioner (with prescriptive authority and qualified to make the diagnosis)
  - Allows a pharmacist to provide approved patient care services via established protocols.

24

---

---

---

---

---

---

---

---

---

---



**FORMULARY / PROTOCOL COMPENDIA**

- [OAR 855-115-0340 Services: Prescribing - Formulary Compendium](#)
  - A Pharmacist may prescribe, according to [OAR 855-115-0330](#) and [OAR 855-115-0335](#), a FDA-approved drug and device listed in the following compendium, pursuant to a diagnosis by a health care practitioner who has prescriptive authority and who is qualified to make the diagnosis. The diagnosis must be documented.
  - Formulary list includes blood sugar testing supplies, inhalation spacers, blood pressure monitors, etc.
- [OAR 855-115-0345 Services: Prescribing - Protocol Compendium](#)
  - A Pharmacist may prescribe, according to [OAR 855-115-0330](#) and [OAR 855-115-0335](#), FDA-approved drugs and devices listed in the following compendium, pursuant to a statewide drug therapy management protocol.
  - Protocols for contraception, vaccinations, tobacco cessation, HIV PEP/PrEP, etc.

25

---

---

---

---

---

---


---

---

---

---

**RESOURCES**  
MODULE III



26

---

---

---

---

---

---


---

---

---

---

**WEBSITE**



[www.oregon.gov/pharmacy](http://www.oregon.gov/pharmacy)

27

---

---

---

---

---


---

---

---

---

---



28

---

---

---

---

---


---

---

---

---

---



29

---

---

---

---

---


---

---

---

---

---



30

---

---

---

---

---

---

---

---


---

---

**JDO** Duplicate- also in module I  
DAVIS Jen \* BOP, 2024-04-03T16:49:48.991

**COMPLIANCE OFFICER ON DUTY**

- Email [pharmacy.compliance@bop.oregon.gov](mailto:pharmacy.compliance@bop.oregon.gov) or call 971-673-0001
- Legal Advice vs. Legal Information
  - Agency staff can provide information about the Board's statutes and rules.
  - Agency staff may be able to provide other information, such as a Newsletter article where the topic has been addressed.
  - Agency staff can point you to the Board's laws and rules but cannot provide you with legal advice as to how the law or rule applies to a specific situation.
  - Agency staff cannot tell you what the Board will or will not do in any specific situation — there is a process by which the Board makes those decisions.
- Resources
  - Oregon Administrative Rules [Chapter 855](#)
  - Oregon Revised Statutes [Chapter 689](#) and [Chapter 475](#)
  - Public Records Request: Please note that there may be fees associated with the production of records, see [standard fee schedule](#).



31

---

---

---

---



---

---

---

---

- For board-approved CPE credit, enter codes for all 3 modules, complete the learning assessment & program evaluation at <https://www.oregon.gov/pharmacy/Pages/PharmacistinCharge.aspx>
  - Program is board-approved, not ACPE approved and will not show up in CPE Monitor
  - You will receive a course completion certificate via email within 8 weeks of completing the learning assessment & program evaluation.
- Please provide feedback to enhance future programs.
- Questions? Contact us directly
  - Phone: 971-673-0001 / Fax: 971-673-0002
  - General Inquiries - [pharmacy.board@bop.oregon.gov](mailto:pharmacy.board@bop.oregon.gov)
  - Compliance Inquiries - [pharmacy.compliance@bop.oregon.gov](mailto:pharmacy.compliance@bop.oregon.gov)
  - Licensing Inquiries - [pharmacy.licensing@bop.oregon.gov](mailto:pharmacy.licensing@bop.oregon.gov)
  - [Controlled Substance Resources](#)
  - [PIC Info & Resources](#)

32

---

---

---

---

---

---

---

---